Effect of anti-tuberculosis drugs on liver function of acquired immune deficiency syndrome patients complicated with tuberculosis

doi:10.3877/cma.j.issn.1674-1358.2017.03.011

Abstract

Abstract:

Objective

To investigate the effect of anti-tuberculosis drugs on liver function of patients with acquired immune deficiency syndrome (AIDS) complicated with tuberculosis (TB).

Methods

Total of 60 patients with AIDS/TB hospitalized from April 2013 to August 2015 in our hospital were collected as the observation group, while 60 cases with TB were selected as the control group. Patients of both groups were treated with anti-tuberculosis drugs, and the indexes changes of liver function, liver function injury and adverse reactions after treatment were compared, respectively.

Results

The TBil and ALT levels of patients of both groups were with no significant differences before treatment (t = 0.952, P = 0.343; t = 0.608, P = 0.544). After treatment, the levels of TBil and ALT in patients of observation group were significantly higher than those of patients in control group (t = 10.110, P < 0.001; t = 26.098, P < 0.001). The proportion of liver damage of patients in observation group was 46.7%, which was significantly higher than that (21.7%) of the control group (χ² = 8.336, P = 0.004). The period of liver function impairment of the observation group was significantly shorter than that of the control group, while the recovery period of liver function damage was significantly longer than that of the control group (t = 11.970, P < 0.001; t = 9.693, P < 0.001). The incidence of adverse reaction of patients in observation group was 20.0%, which was significantly higher than that (8.3%) of the control group (χ² = 5.634, P < 0.001). The proportion of CD4⁺ T cells of patients with liver injury was (32.82 ± 4.67)%, and that of patients without liver damage was (39.66 ± 4.85)%, with significant difference (t = 7.419, P < 0.001).

Conclusions

During the course of anti-tuberculosis treatment, patients with AIDS/TB had a greater influence on liver function and were more likely to suffer from liver function damage.

Key words: Acquired immune deficiency syndrome, Tuberculosis, Anti-tuberculosis treatment, Liver function

Huanhuan Cao. Effect of anti-tuberculosis drugs on liver function of acquired immune deficiency syndrome patients complicated with tuberculosis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(03): 260-264.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.03.011

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I03/260

Figures/Tables 2

References 25

[1]	于珊珊, 吴荣荣, 凌海慧, 等. 对艾滋病合并肺结核患儿实施药学监护的探讨[J]. 中国医药,2012,7(11):1359-1360.
[2]	邓福球, 陈梅娟, 卫奕荣, 等. 艾滋病合并结核病98例临床分析[J]. 中国皮肤性病学杂志,2011,25(12):958-959.
[3]	唐新华, 李观. 结核抗体, C-反应蛋白在结核病合并艾滋病中的检测及临床意义[J]. 实用临床医药杂志,2014,18(11):43-45.
[4]	吴波, 张舜, 胡代玉, 等. 重庆市结核病患者患艾滋病病毒感染现况调查[J]. 重庆医学,2013,42(19):2249-2251.
[5]	Han SH, Zhou J, Lee MP, et al. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: Results from the TREAT Asia HIV Observational Database[J]. HIV Med,2014,15(2):77-85.
[6]	Mehra S, Golden NA, Dutta NK, et al. Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus[J]. J Med Primatol,2011,40(4):233-243.
[7]	JT Mattila, Diedrich CR, Lin PL, et al. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation[J]. J Immunol,2011,186(6):3527-3537.
[8]	Camoni L, Regine V, Boros S, et al. AIDS patients with tuberculosis: Characteristics and trend of cases reported to the National AIDS Registry in Italy, 1993-2010[J]. Eur J Public Health,2013,23(4):658-663.
[9]	杨铭, 岳冀, 李曦, 等. 结核病合并HIV/AIDS发病情况分析[J]. 临床肺科杂志,2012,17(5):845-846.
[10]	赖钰基, 成诗明, 周林, 等. 3省艾滋病病毒感染对结核病控制影响[J]. 中国公共卫生,2013,29(12):1738-1741.
[11]	童学成, 陈国春, 濮翔科, 等. 结核感染T细胞斑点试验对艾滋病合并肺结核的临床诊断价值[J]. 中华医院感染学杂志,2014,24(14):3632-3634.
[12]	秦刚, 刘先进, 沈毅, 等. 艾滋病合并结核病18例临床分析[J]. 南通大学学报(医学版),2013,33(1):77-78.
[13]	Grinsztejn B, DeCastro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial[J]. Lancet Infect Dis,2014,14(6):459-467.
[14]	刘惠, 闻颖. 艾滋病患者和HIV感染者中结核潜伏性感染的诊断与预防性治疗[J]. 中国防痨杂志,2016,38(1):57-60.
[15]	Sauzullo I, Mengoni F, Ermocida A, et al. Interferon-y release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response[J]. New Microbiol,2014,37(2):153-161.
[16]	Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study[J]. J AIDS,2012,60(4):377-383.
[17]	郑志刚, 崔哲哲, 黄敏莹, 等. 广西壮族自治区结核分枝杆菌/HIV联合感染患者抗病毒治疗对死亡影响的分析[J]. 中华流行病学杂志,2015,36(2):124-127.
[18]	连晓明. HIV/AIDS合并结核病的临床研究进展[J]. 海南医学,2013,24(15):2274-2276.
[19]	陈仁芳, 杨琦恩, 陆宇红, 等. T-SPOT. TB在艾滋病合并结核感染诊断中的应用[J]. 江苏医药,2014,40(5):532-534.
[20]	吴念宁, 黄绍标, 陈万, 等. 艾滋病合并结核病患者抗结核治疗中肝损伤情况调查[J]. 临床肺科杂志,2012,17(3):461-462.
[21]	许琳, 杨蕊, 高小娇, 等. 结核病/艾滋病双重感染患者抗结核治疗生存分析[J]. 现代预防医学,2015,42(19):3587-3589, 3605.
[22]	Limmahakhun S, Chaiwarith R, Nuntachit N, et al. Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, Thailand[J]. Int J STD AIDS,2012,23(6):414-418.
[23]	汪雯, 张宏伟, 姜太一, 等. 艾滋病合并结核感染233例临床分析[J]. 北京医学,2011,33(12):986-988.
[24]	Maruza M, Albuquerque MF, Braga MC, et al. Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study[J]. Int J Tuberc Lung Dis,2012,16(5):618-624.
[25]	孙阳, 裴志恒, 林萍, 等. 艾滋病患者抗结核治疗中口腔和肠道菌群的意义[J]. 中华传染病杂志,2014,32(3):182-186.

组别	例数	TBil（μmol/L）		ALT（IU/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	60	7.6 ± 1.2	17.2 ± 5.1	32.2 ± 4.6	142.3 ± 16.8
观察组	60	7.8 ± 1.1	26.8 ± 5.3	31.7 ± 4.4	231.6 ± 20.5
t值		0.952	10.110	0.608	26.098
P值		0.343	< 0.001	0.544	< 0.001

组别	例数	TBil（μmol/L）		ALT（IU/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	60	7.6 ± 1.2	17.2 ± 5.1	32.2 ± 4.6	142.3 ± 16.8
观察组	60	7.8 ± 1.1	26.8 ± 5.3	31.7 ± 4.4	231.6 ± 20.5
t值		0.952	10.110	0.608	26.098
P值		0.343	< 0.001	0.544	< 0.001

组别	例数	轻度损伤	中度损伤	重度损伤	损伤比例
对照组	60	6（10.0）	5（8.3）	2（3.3）	13（21.7）
观察组	60	14（23.3）	9（15.0）	5（8.3）	28（46.7）
χ²值		3.840	1.294	1.365	8.336
P值		0.050	0.255	0.243	0.004

组别	例数	轻度损伤	中度损伤	重度损伤	损伤比例
对照组	60	6（10.0）	5（8.3）	2（3.3）	13（21.7）
观察组	60	14（23.3）	9（15.0）	5（8.3）	28（46.7）
χ²值		3.840	1.294	1.365	8.336
P值		0.050	0.255	0.243	0.004

Please choose a citation manager

Content to export